These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18335161)

  • 1. Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.
    Müller T; Muhlack S
    J Neural Transm (Vienna); 2008 Jun; 115(6):851-5. PubMed ID: 18335161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease.
    Müller T; Welnic J; Woitalla D; Muhlack S
    Neurosci Lett; 2007 Jul; 422(2):119-22. PubMed ID: 17590511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.
    Müller T; Welnic J; Muhlack S
    J Neural Transm (Vienna); 2007 Mar; 114(3):347-50. PubMed ID: 16932991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of exercise on reactivity and motor behaviour in patients with Parkinson's disease.
    Müller T; Muhlack S
    J Neurol Neurosurg Psychiatry; 2010 Jul; 81(7):747-53. PubMed ID: 20478845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease.
    Müller T; Muhlack S
    Clin Neuropharmacol; 2007; 30(2):101-6. PubMed ID: 17414942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease.
    Kelly NA; Ford MP; Standaert DG; Watts RL; Bickel CS; Moellering DR; Tuggle SC; Williams JY; Lieb L; Windham ST; Bamman MM
    J Appl Physiol (1985); 2014 Mar; 116(5):582-92. PubMed ID: 24408997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
    Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S
    J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
    Kestenbaum M; Fahn S
    Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
    Qu Y; Lai WL; Xin YR; Zhu FQ; Zhu Y; Wang L; Ding YP; Xu Y; Liu HF
    AAPS PharmSciTech; 2019 Sep; 20(8):312. PubMed ID: 31529266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise improves efficacy of levodopa in patients with Parkinson's disease.
    Muhlack S; Welnic J; Woitalla D; Müller T
    Mov Disord; 2007 Feb; 22(3):427-30. PubMed ID: 17226855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
    Nausieda PA; Hsu A; Elmer L; Gil RA; Spiegel J; Singer C; Khanna S; Rubens R; Kell S; Modi NB; Gupta S
    J Parkinsons Dis; 2015; 5(4):837-45. PubMed ID: 26444090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial.
    Shin CM; Lee YJ; Kim JM; Lee JY; Kim KJ; Choi YJ; Kim N; Lee DH
    Parkinsonism Relat Disord; 2018 Sep; 54():84-89. PubMed ID: 29705555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson disease.
    Lopane G; Contin M; Scaglione C; Albani F; Baruzzi A; Martinelli P
    Clin Neuropharmacol; 2010; 33(5):254-6. PubMed ID: 20852413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
    Modi NB; Mittur A; Rubens R; Khanna S; Gupta S
    Clin Neuropharmacol; 2019; 42(1):4-8. PubMed ID: 30520758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
    J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T
    Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.